View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Guy Sips ... (+10)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen

Guy Sips ... (+5)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

UCB Presents supportive three-year Bimzelx data in HS at EHSF

UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Monitoring for a Pullback We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $257 on IWM (up from $245) continue to hold. We continue to see deterioration in market dynamics, and while we expect a period of consolidation/pullback, the afo...

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

UCB Model update ahead of FY25 results

Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...

 PRESS RELEASE

IBA – Share buyback

IBA – Share buyback Louvain-la-Neuve, Belgium, February 2nd, 2026 – 6PM CET – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of a share buyback program, effective as of February 3rd, 2026, in application of article 7:215 of the Belgian Companies and Associations Code. By a decision of the Board of Directors of March 18th, 2025, approving the Stock Option Plan 2025, and pursuant to the authorization given by the EGM of September 4th, 2023, IBA launched a program to buy back own shares through a mandate given to a...

 PRESS RELEASE

IBA – Rachat d’Actions Propres

IBA – Rachat d’Actions Propres Louvain-la-Neuve, Belgique, 2 février 2026 – 18h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules, annonce aujourd’hui le lancement d’un programme de rachat d’actions propres à compter du 3 février 2026, en application de l’article 7:215 du Code belge des sociétés et des associations. Par une décision du Conseil d’administration du 18 mars 2025, approuvant le Plan de Stock-Options 2025, et conformément à l’autorisation donnée par l’AGE du 4 septembre 2023, IBA a lancé un programme de rachat d’actio...

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

UCB Kygevvi receives positive CHMP opinion in ultra-rare disease TK2d

Friday during trading hours, UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of pediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. Following the positive CHMP opinion...

 PRESS RELEASE

Participation notifications by UBS Group AG

Participation notifications by UBS Group AG Press release                                                                  Regulated information Brussels, January 29, 2026, 17:45 CET  In line with Belgian transparency legislation (Law of May 2, 2007), UBS Group AG recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%.  Here is a summary of the notifications:  Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total 21 January 2026 0.00% 0.00% 0.00% 23 ...

 PRESS RELEASE

Notifications de participation par UBS Group AG

Notifications de participation par UBS Group AG Communiqué de presse                                                                 Information réglementéeBruxelles, le 29 janvier 2026 - 17h45 CET  Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), UBS Group AG a envoyé récemment à Solvay les notifications de transparence suivante indiquant avoir franchi le seuil de 3%.  Voici un résumé des notifications:  Date de dépassement de seuil Droits de vote Instruments financiers équivalents Total 21 janvier 2026 0,00% 0,00% 0,00% 23 janvie...

 PRESS RELEASE

Participatiemeldingen van UBS Group AG

Participatiemeldingen van UBS Group AG Persbericht                                                                 Gereglementeerde informatie Brussel, 29 januari 2026 - 17u45 CET  In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft UBS Group AG onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden.  Hier is een samenvatting van de bewegingen:  Datum waarop de drempel werd overschreden Stemrechten Aan stemrechten gelijkgestelde financiële instrumenten Totaal 21 januari 2026 0,00% 0...

 PRESS RELEASE

Participation notifications by Citigroup Inc.

Participation notifications by Citigroup Inc. Press release                                                                  Regulated information Brussels, January 28, 2026, 17:45 CET  In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%.  Here is a summary of the notifications:  Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total January 19, 2026 0.56% 2.51 3.06% ...

 PRESS RELEASE

Notifications de participation par Citigroup Inc.

Notifications de participation par Citigroup Inc. Communiqué de presse                                                                 Information réglementée Bruxelles, le 28 janvier 2026 - 17h45 CET  Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), Citigroup Inc. a envoyé récemment à Solvay les notifications de transparence suivantes indiquant avoir franchi le seuil de 3%.  Voici un résumé des notifications:  Date de dépassement de seuil Droits de vote Instruments financiers équivalents Total 19 janvier 2026 0,56% 2,51 3,06% 22 ja...

 PRESS RELEASE

Participatiemeldingen van Citigroup Inc.

Participatiemeldingen van Citigroup Inc. Persbericht                                                          Gereglementeerde informatie Brussel, 28 januari 2026 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft Citigroup Inc. onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de bewegingen: Datum waarop de drempel werd overschredenStemrechtenAan stemrechten gelijkgestelde financiële instrumentenTotaal19 januari 20260,56%2,513,06%22...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Conditional approval for the acquisition of Delfood / Bekaert: Acquires Bridgestone's €80m tyre cord business in China and Thailand / KPN: In-line Q4, 2026 guidance, cash returns / NSI: Results in line, further vacancy weighing on 2026 and cautious tone on new developments / UCB: Cimzia included in Medicare's price negotiations for 2028

Livio Luyten ... (+4)
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Solvay Taking a more cautious stance, lowering target price

Increased pressure in the soda ash market prompts us to take a more conservative approach with regards to contract terms for the coming years, resulting in a reduction of our group EBITDA forecasts for 2026-2028 by between 6-11%. The dividend policy of a stable to increasing dividend from a € 2.43 base looks increasingly generous as servicing the dividend representing the vast majority of current FCF generation, limiting the group's ability to pursue other growth initiatives. Despite the attract...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch